Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05902533 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation

Study acronym: REDEL
StatusActive, Not Recruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 18, 2025 (before its estimated August 14, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Recruiting to Active, Not Recruiting Site details revised at 3 of 3 sitesv5 Show 1 more changeShow less
    • Site details revised at 3 of 3 sites
  2. Study sites: 2 to 3v4
  3. Study sites: 1 to 2v3
  4. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Jul 5, 2026 to Aug 14, 2026 · Completion date: Jul 5, 2029 to Aug 14, 2029 · Start date changed from estimate of Jul 5, 2023 to Aug 14, 2023 · 1 morev2 Show 4 more changesShow less
    • Primary completion date: Jul 5, 2026 to Aug 14, 2026
    • Completion date: Jul 5, 2029 to Aug 14, 2029
    • Start date changed from estimate of Jul 5, 2023 to Aug 14, 2023
    • Site details revised
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To determine the efficacy of reduced elective nodal radiation in anal cancer patients undergoing chemoradiation in reducing toxicity compared to standard nodal irradiation.
Trial Details
NCT Number NCT05902533
Lead Sponsor University of Cincinnati
Conditions Anal Cancer
Enrollment 33 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov